Alaunos Therapeutics

Alaunos Therapeutics is a biotechnology startup founded in 2005, based in Houston, TX, with a mission to "Attacking solid tumors with TCRs." The company is dedicated to advancing the treatment of solid tumors through adoptive TCR-T cell therapy. Alaunos aims to strike cancer at its core by engineering cell therapies that target neoantigens arising from genomic mutations. Their innovative discovery engine has led to the development of proprietary, rapid, cost-effective solutions to deliver tumor-specific killer T cells to large cancer patient populations with unmet clinical needs. This clinical stage cellular immuno-oncology company received a significant $15.70M Post-IPO Equity investment on 29 November 2022. The latest investment underscores the promising potential and investor confidence in Alaunos Therapeutics. This funding will likely propel the company forward in its mission to make a difference in the lives of cancer patients and their families. With its location in Houston, TX, which is home to the largest medical center in the world, Alaunos is positioned in an environment conducive to medical innovation. Additionally, being situated in a state with no state income tax and a low cost of living, the company can attract and retain top talent while maximizing resources for further research and development initiatives. Alaunos Therapeutics presents an exciting opportunity for venture capitalists looking to invest in the biotechnology and pharmaceutical industries. The focus on treating solid tumors through cutting-edge therapies and the recent significant investment position Alaunos as a noteworthy player in the immuno-oncology space. For more information about Alaunos Therapeutics, interested parties can visit www.alaunos.com and explore potential collaborations or investment opportunities.